Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease
Lawrence S. Honig(Columbia University), Lynn D. Kramer(Eisai (United States)), Shobha Dhadda(Eisai (United States)), Steven M. Hersch(Eisai (United States)), Luigi Giorgi(Eisai (United Kingdom)), Derk D. Purcell(BioClinica (United States)), Christopher H. van Dyck(Yale University), David Li(University of Strathclyde), Marwan N. Sabbagh(Cleveland Clinic), Michelle Gee(Eisai (United Kingdom)), Michael C. Irizarry(Eisai (United States)), Reisa A. Sperling(Harvard University), André Matta(Eisai (United States)), Michio Kanekiyo(Eisai (United States))
Cited by 150
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Lecanemab in Early Alzheimer’s Disease
|New England Journal of Medicine|2022|5k
Diagnosis and management of dementia with Lewy bodies
|Neurology|2017|4.4k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k